Eupraxia Pharmaceuticals (EPRX) investor relations material

Company overview and business model

• Clinical-stage biotechnology company leveraging proprietary Diffusphere™ technology for targeted, prolonged drug delivery in areas of unmet medical need.

• Two main clinical programs: EP-104GI for eosinophilic esophagitis (EoE) and EP-104IAR for chronic osteoarthritis (OA) knee pain, both using extended-release fluticasone propionate.

• EP-104GI is in Phase 1b/2 and Phase 2b trials across multiple countries; EP-104IAR completed Phase 2b and is seeking late-phase development funding.

• Strategy includes potential partnerships for development/commercialization and expansion into additional indications and pipeline candidates.

Financial performance and metrics

• As of March 31, 2026, held $58.5 million in cash and equivalents, expected to fund operations into the second half of 2028.

• History of negative operating cash flow and ongoing net losses expected as R&D and clinical trial investments continue.

• Raised approximately $63.2 million in a brokered public offering in February 2026.

Use of proceeds and capital allocation

• Net proceeds from offerings will be detailed in prospectus supplements; proceeds may fund negative cash flow, R&D, clinical trials, and potential acquisitions.

• Capital previously allocated to EP-104IAR redirected to EP-104GI development pending partnership outcomes.